BioCardia, Inc. announced that Mark Schwartz has joined the company as Vice President of Clinical Affairs, effective November 1, 2018. Schwartz brings extensive leadership experience in the design and execution of clinical studies for medical devices in the heart leading to regulatory approvals for such industry leaders as Boston Scientific, The Sorin Group and Guidant, among others. Schwartz comes to the company from EBR Systems, where he served as Vice President of Clinical and Regulatory Affairs for the developer of cardiac resynchronization therapy. Previously, he served as Senior Director of Clinical Affairs for The Sorin Group. There, he had oversight for IDE, research and post-market studies for a variety of cardiac devices, and was responsible for developing clinical, regulatory, market access and health economics strategies.